iVascular's Angiolite BTK Sirolimus-Eluting Stent Launched in Europe
July 18, 2017—iVascular announced the European launch of its Angiolite BTK sirolimus-eluting stent. The device has received CE Mark approval for treating chronic and acute arterial lesions in limbs below the knee (BTK) to improve blood flow in severe claudication and critical limb ischemia. Angiolite BTK uses iVascular's nanotechnology coating that yields a thin, multilayer coating with optimal kinetics. The company is based in Barcelona, Spain.
Peter Goverde, MD, a vascular surgeon with ZNA Stuivenberg Hospital in Antwerp, Belgium, led the clinical study for the device. The study demonstrated a 6-month primary patency rate of 90%, amelioration in wound healing, and reduction of major amputation.
In iVascular's press release, Dr. Goverde commented, "Having the right bail-out options when performing BTK angioplasty is extremely important in saving limbs. The latest-generation drug-eluting stents, like the dedicated Angiolite BTK, can give you a solution and improve the outcome of your treatment.”